Sutter Health Research Enterprise
2800 L Street, Suite 300
Sacramento, CA, 95816
(916) 454-6822
simr@sutterhealth.org
Dr. Rohatgi is a research oncologist at SIMR.
Sutter Health Research Enterprise
2800 L Street, Suite 300
Sacramento, CA, 95816
(916) 454-6822
simr@sutterhealth.org
Sutter Health Research Enterprise
2800 L Street, Suite 300
Sacramento, CA, 95816
(916) 454-6822
simr@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Adjuvant Breast (EndoPredict Extended Endocrine Trial EXET Myriad)
To evaluate the impact of using EndoPredict clinically to inform treatment decisions for extended endocrine therapy and the subsequent impact on patient outcome
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.
Status: Active, Recruiting
Lung Cancer (AbbVie M14-239)
Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Investigators: Deepti Behl MD, Nitin Rohatgi MD
Status: Active, Recruiting
Novocure LUNAR
Effect of Tumor Treating Fields Concurrent W/ Standard of Care Therapies for Treatment of Stage 4 NSCLC following Platinum Failure (LUNAR)
Investigators: Deepti Behl MD, Stacy D'Andre MD, Nitin Rohatgi MD, Melissa Williams M.D.
Status: Active, Not Recruiting
RESILIENT-Ipsen (MM-398-01-03-04)
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection vs Toptecan in patients with SCLC
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Rajeswari Chellappah M.D., Brian K. Kim M.D, Jasdeepa Nagi M.D., Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.
Status: Active, Not Recruiting
The Pathfinder 2 Study (Grail)
Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Investigators: Deepti Behl MD, Kristie A. Bobolis M.D., Alex J. Garica-Young MD, Charles McDonnell MD, FACR, Sivakumar Reddy M.D., Nitin Rohatgi MD
Status: Active, Recruiting
Publications
Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas
Research Studies
Genomic Health Oncotype DX AR-V7
Genomic Health 09-060
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D., David S Yee M.D., MPH